Women Health Therapeutics Market - Global Industry Analysis, Market Size, Share, Trends, Analysis, Growth And Forecasts 2011 - 2017
- Transparency Market Research
- Ongoing
- Healthcare
Report Description
Market Size and
Forecast
The women health therapeutics market
is growing rapidly due to increasing awareness among patients &
physicians and introduction of new therapies in the market. The women
health therapeutics market was USD 14,530 million in 2010 and is expected
to reach at USD 24,669 million by 2017 at an estimated CAGR of 7.9% during
2010-2017.
The menopause therapeutics market
segment and post menopause osteoporosis market segment are expected to
have maximum potential in women health therapeutics market during the
forecast period.
Market Trends
Currently the menopause therapeutics
market is driven by hormone therapeutics, which is less health concerned.
New entrance of Non-hormones therapeutics is expected to compete with the
currently marketed drugs and will significantly change the market
dynamics.
The current women health therapeutics
market has strong pipe-line of first-in-class molecules in clinical
development such as Pristiq, Aprela, Menerba, Elagolix and Cetrorelix.
Apart from this, porlia a first-in-class drug newly introduced by Amgen
Inc. it is expected to drive the post menopausal osteoporosis therapeutics
market in term of volume and expected to generate revenue of USD 1 billion
annually during forecasted period. Novel, non-hormonal therapeutics is
expected to become more popular during the forecasted period for treatment
of menopause therapeutics market. Thus there are huge opportunities for
new non hormone therapeutics drugs in women health therapeutics
market.
Industry
Analysis
The women health therapeutics market
is consolidated as top five players in the market accounts for more than
80% of the total women health therapeutics market. Eli Lilly is the
current market leader by accounting for approximately 26% of the total
women health therapeutics market. Eli Lilly leadership is driven by two
major selling drugs, Evista and Forteo for the treatment of post menopause
osteoporosis. Merck accounts for 16% share of women health therapeutics
market while Pfizer holds 15% share of women health therapeutics
market.
Have query on this report?
Make an Enquiry
Success Stories
Our Clients
More from Healthcare
Popular Reports
Pharmaceuticals and Healthcare
Global Bionic Ears Market Professional Survey Report 2017Pharmaceuticals and Healthcare
Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017Pharmaceuticals and Healthcare
Hepatitis Drug Development Pipeline Review, 2017